20000317o-3
IPOS reference

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 9/08, 31/47, 47/02, 47/32, 47/18

A1

(11) International Publication Number: WO 99/32087

(43) International Publication Date: 1 July 1999 (01.07.99)

(21) International Application Number: PCT/JP98/05699

(22) International Filing Date: 16 December 1998 (16.12.98)

(30) Priority Data:

9/353039	22 December 1997 (22.12.97)	JP
10/298550	20 October 1998 (20.10.98)	JP

(81) Designated States: AU, BR, CA, CN, ID, IN, KR, MX, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(71) Applicant *(for all designated States except US)*: OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SUGAHARA, Yuji [JP/JP]; 1-36, Nakanokoshi, Aza-Nakase, Nakakirai, Matsushige-cho, Itano-gun, Tokushima 771-0212 (JP). SAKATA, Kazuya [JP/JP]; 117-1, Aza-Kaya, Tainohama, Kitajima-cho, Itano-gun, Tokushima 771-0204 (JP). ODOMI, Masaaki [JP/JP]; #603, Satomi-Daini-Building, 19-1, Nakasu-cho 3-chome, Tokushima-shi, Tokushima 770-0856 (JP).

(74) Agent: KAMEI, Hirokatsu; AI Association of Patent and Trademark Attorneys, 12F, Jyutakukinyukoko-Sumitomoseimei Building, 5-20, Minamihommachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0054 (JP).

(54) Title: WATER-SOLUBLE EYE DROP

(57) Abstract

Disclosed is a water-soluble eye drop comprising (a) at least one selected form carteolol and an acid addition salt thereof, (b) at least one acrylic polymer selected from a straight-chain type polyacrylic acid and a pharmaceutically acceptable water-soluble salt thereof, and (c) at least one selected from a water-soluble alkali metal salt and a water-soluble amine. The water-soluble eye drop of the present invention has a remarkably long duration time of drug efficacy, and is superior in intraocular pressure inhibition action and is effective for treatment of glaucoma.